Interstitial Lung Disease.

Chung, Man Pyo

doi:2011.71.3.163

Tuberc Respir Dis > Volume 71(3); 2011 > Article

Review Article

Tuberculosis and Respiratory Diseases 2011;71(3):163-171.
DOI: https://doi.org/10.4046/trd.2011.71.3.163 Published online September 1, 2011.

Interstitial Lung Disease.

Man Pyo Chung

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. mp.chung@samsung.com

Abstract

Recently published articles on interstitial lung disease (ILD) have focused on the accurate diagnosis of idiopathic pulmonary fibrosis (IPF), serum biomarkers, acute exacerbation of IPF, the prognostic factors of ILD and the trial of new treatment. In particular, reports on the serum biomarkers such as CC-chemokine ligand 18, surfactant protein, circulating fibrocytes, and acute exacerbation of IPF are sufficient to be mentioned here. Pirfenidone therapy is the most important trial for the treatment of IPF. Other newer treatment trials such as interferon-gamma, sildenafil and imatinib have been reported to be unsuccessful. On the other hand, the sirolimus trial for lymphangioleiomyomatosis is promising. Combined pulmonary fibrosis and emphysema and IgG4-related disease are established to be the new disease entities of ILD.

Key Words: Lung Disease, Interstitial, Idiopathic Pulmonary Fibrosis, Pirfenidone